Andres Valkna
University of Tartu
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Andres Valkna.
Neuroscience Letters | 1995
Andres Valkna; Anders Juréus; Ello Karelson; Mihkel Zilmer; Tamas Bartfai; Ülo Langel
Rat galanin inhibits basal as well as forskolin-stimulated adenylate cyclase activity in rat ventral and dorsal hippocampus. The inhibition of adenylate cyclase activity, both basal and forskolin-stimulated, is characterised by IC50 values being 250-fold lower in ventral hippocampus (IC50 = 1.1 nM) compared to the dorsal hippocampus (IC50 = 270 nM). The maximal inhibition of basal and forskolin-stimulated adenylate cyclase activity in both ventral and dorsal hippocampus in the presence of 10 microM rat galanin is 34-45%. The analysis of the binding data obtained with 125I-labelled Tyr26-porcine galanin as a tracer reveals similar binding constants for rat galanin in both ventral and dorsal hippocampus with 4.8-fold higher concentration of galanin receptors in the ventral hippocampus. Putative galanin receptor subtype differences between the ventral and dorsal hippocampus have been noted by Hedlund et al. (Eur. J. Pharmacol., 224 (1992) 203-205). This study yields further confirmation for the existence of different galanin receptor subtypes or for differential coupling of galanin receptors to the adenylate cyclase in the dorsal versus ventral hippohampus.
Neuropeptides | 2000
Khadijeh Rezaei; Külliki Saar; Ursel Soomets; Andres Valkna; J. Näsman; M. Zorko; K. Åkerman; T. Schroeder; Tamas Bartfai; Ülo Langel
To determine the domains essential for G-protein coupling of the human galanin receptor type 1 (GalR1), we have used both GalR1 mutants and synthetic receptor-derived peptides in(125)I-galanin and [(35)S]-GTPgammaS binding studies. Replacement of potential phosphorylation sites by Leu in the third intracellular loop (IC3) of GalR1 did not affect K(D)values for the receptor. Peptides derived form the IC3 loop, and especially the N-terminal part of it were able to increase the rate of [(35)S]-GTPgammaS binding to the trimeric Gialpha1beta1gamma2, but not to Gsalphabeta1gamma2, whereas the peptides corresponding to the IC1 and IC2 loops had no such effect. IC3 loop peptides also inhibited the binding of(125)I-galanin to GalR1 in membranes from Rin m5F cells. Our results suggest that the IC3 loop of GalR1, especially its N-terminal part, defines the coupling of the receptor to the Gialpha1beta1gamma2 protein and consequently, to the signal transduction cascade.
Regulatory Peptides | 2001
Külliki Saar; Riina Mahlapuu; Erki Laidmäe; Andres Valkna; Ulrika Kahl; Ello Karelson; Ülo Langel
In this work, we studied a novel chimeric peptide, M242, galanin(1-13)-[D-Trp(32)]-neuropeptide Y(25-36)amide, and examined its properties in comparison with its parent peptide, M32, galanin(1-13)-neuropeptide Y(25-36)amide, a previously known high-affinity ligand for galanin receptors, and galanin itself. Binding assays performed in Bowes cells known to express human galanin receptor type 1 (hGalR1) and in Chinese hamster ovary cells overexpressing human galanin receptor type 2 (hGalR2) revealed that all three ligands had comparable affinities: at hGalR1<1 nM and at hGalR2<10 nM. However, in rat hippocampal membranes M242 had a 24-fold lower affinity than galanin (9.4 vs. 0.4 nM) and 134-fold lower affinity than M32 (9.4 vs. 0.07 nM). In the same tissue, we also examined the effects of these peptides on adenylate cyclase activity. M32 showed a weak antagonistic behaviour but M242 acted as a potent biphasic regulator of adenylate cyclase. In conclusion, we present and characterise a new peptide M242, which could be a useful tool in studies of galaninergic signalling.
Hybridoma | 2008
Silja Laht; Kati Meerits; Harri Altroff; Helena Faust; Robert Tsaney; Priit Kogerman; Lilian Järvekülg; Viiu Paalme; Andres Valkna; Sirje Timmusk
Gli3 is a key regulator of development, controlling multiple patterning steps. Here we report the generation of a scFv antibody specific to the repressor domain of human Gli3. We show that this scFv retains the binding capacity of its parent anti-Gli3 monoclonal antibody derived from hybridoma clone 5E1. When expressed in mammalian cells, the anti-Gli3 scFv co-localizes with intracellular Gli3. Immunocytochemical staining of the intrabody in Gli3-positive TM4 cells shows a distinct perinuclear cytoplasmic localization. Such a scFv constitutes a useful tool for studying transcriptional regulation of the hedgehog pathway in mammals and offers a starting point for developing novel Gli-related therapeutic intrabodies.
Nature Biotechnology | 1998
Margus Pooga; Ursel Soomets; Mattias Hällbrink; Andres Valkna; Külliki Saar; Khadijeh Rezaei; Ulrika Kahl; Jing-Xia Hao; Xiao-Jun Xu; Zsuzsanna Wiesenfeld-Hallin; Tomas Hökfelt; Tamas Bartfai; Ülo Langel
Journal of Controlled Release | 2005
Kalle Kilk; Samir El-Andaloussi; Peter Järver; Anne Meikas; Andres Valkna; Tamas Bartfai; Priit Kogerman; Madis Metsis; Ülo Langel
Archive | 1998
Ülo Langel; Tamas Bartfai; Margus Pooga; Andres Valkna; Külliki Saar; Mattias Hällbrink
Archive | 1998
Ülo Langel; Tamas Bartfai; Margus Pooga; Andres Valkna; Külliki Saar; Mattias Hällbrink
Hybridoma | 2007
Reet Hunt; Olga Bragina; Monika Drews; Lagle Kasak; Sirje Timmusk; Andres Valkna; Priit Kogerman; Lilian Järvekülg
Archive | 2008
Taavi Päll; Wally Andderson; Lagle Kasak; Anne Pink; Priit Kogerman; Aire Allikas; Andres Valkna